New methods to improve drug delivery and immune response in pancreatic cancer
Novel Strategies to Enhance Drug Delivery and Tumor Immunogenicity in Pancreatic Cancer
This study is testing a new virus treatment for pancreatic cancer that aims to attack cancer cells directly and boost the body's immune response, with the hope of making treatments more effective and helping patients live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project ID | NIH-10908003 on NIH RePORTER |
What this research studies
This research focuses on developing a novel oncolytic virus platform to treat pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. The approach involves using a modified virus that can effectively target and kill cancer cells while also enhancing the immune response against the tumor. By breaking down the dense tumor stroma, which often hinders treatment effectiveness, this strategy aims to improve the delivery of therapeutic agents and increase immune cell infiltration into the tumor. Patients may benefit from improved treatment outcomes and potentially longer survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who have limited treatment options.
Not a fit: Patients with early-stage pancreatic cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise with oncolytic viruses in treating other types of cancer, suggesting potential success for this novel approach in pancreatic cancer.
Where this research is happening
Little Rock, United States
- Univ of Arkansas for Med Scis — Little Rock, United States (Active)
Researchers
- Principal investigator: Nagalo, Bolni Marius — Univ of Arkansas for Med Scis
- Study coordinator: Nagalo, Bolni Marius
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.